华俊, 李岚, 杨媛媛, 刘琪, 张伟, 陈晓良. 68Ga-FAPI-04 PET/CT对胰腺癌的诊断价值及对肿瘤分期的影响[J]. 中国肿瘤临床, 2024, 51(3): 118-123. DOI: 10.12354/j.issn.1000-8179.2024.20231299
引用本文: 华俊, 李岚, 杨媛媛, 刘琪, 张伟, 陈晓良. 68Ga-FAPI-04 PET/CT对胰腺癌的诊断价值及对肿瘤分期的影响[J]. 中国肿瘤临床, 2024, 51(3): 118-123. DOI: 10.12354/j.issn.1000-8179.2024.20231299
shu
Jun Hua, Lan Li, Yuanyuan Yang, Qi Liu, Wei Zhang, Xiaoliang Chen. 68Ga-labeled fibroblast activation protein inhibitor (FAPI)-04 PET/CT in the diagnosis of pancreatic cancer and its influence on clinical staging[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 51(3): 118-123. DOI: 10.12354/j.issn.1000-8179.2024.20231299
Citation: Jun Hua, Lan Li, Yuanyuan Yang, Qi Liu, Wei Zhang, Xiaoliang Chen. 68Ga-labeled fibroblast activation protein inhibitor (FAPI)-04 PET/CT in the diagnosis of pancreatic cancer and its influence on clinical staging[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 51(3): 118-123. DOI: 10.12354/j.issn.1000-8179.2024.20231299
shu

68Ga-FAPI-04 PET/CT对胰腺癌的诊断价值及对肿瘤分期的影响

68Ga-labeled fibroblast activation protein inhibitor (FAPI)-04 PET/CT in the diagnosis of pancreatic cancer and its influence on clinical staging

    摘要
  • 摘要:
    目的 探讨68Ga标记的成纤维细胞激活蛋白抑制剂（fibroblast activation protein inhibitor，FAPI）-04正电子发射断层显像 /X 线计算机体层成像（positron emission tomography and computed tomography，PET/CT）对初诊胰腺癌的诊断价值及对肿瘤分期的影响。
    方法 回顾性收集2021年8月至2023年8月于重庆大学附属肿瘤医院就诊的134例因怀疑胰腺占位的患者临床及影像资料。分析68Ga-FAPI-04 PET/CT 对胰腺癌原发灶及转移灶的诊断价值；并与传统CT比较，分析68Ga-FAPI-04 PET/CT对胰腺癌肿瘤分期的影响。
    结果 共计纳入134例患者，其中胰腺癌127例，良性病变7例。68Ga-FAPI-04 PET/CT对胰腺癌原发灶、区域淋巴结及远处转移灶检出率分别为100%（127/127）、68.63%（35/51），95.35%（41/43）。胰腺癌中位最大标准化摄取值（standard uptake value maxium，SUVmax）为14.92，高于胰腺良性病变中位SUVmax（6.1）（Z=−2.921，P=0.003）。与传统CT比较，68Ga-FAPI PET/CT检查后共有32.28%（41/127）胰腺癌患者TNM分期发生改变。3.94%（5/127）患者改变了治疗方案。
    结论 68Ga-FAPI-04 PET/CT对胰腺癌原发灶诊断具有较高的敏感性，较传统CT可发现更多远处转移病灶，改善患者M分期，有助于全面评估全身肿瘤负荷、制定治疗计划。

     

    Abstract:
    Objective To investigate the diagnostic value of 68Ga-fibroblast activation protein inhibitor (FAPI)-04 positron emission tomography and computed tomography (PET/CT) in patients with newly diagnosed pancreatic cancer and its impact on the initial tumor, node, metastasis (TNM) and clinical stagings.
    Methods Clinical and imaging data of patients suspected of having pancreatic lesions and admitted to Chongqing University Cancer Hospital between August 2021 and August 2023 were analyzed retrospectively. All the patients underwent conventional CT and 68Ga-FAPI-04 PET/CT. Diagnostic value of 68Ga-FAPI-04 PET/CT in primary and metastatic pancreatic cancers was analyzed using pathological findings or follow-up images as the gold standard. The effect of 68Ga-FAPI-04 PET/CT on TNM and clinical stagings of pancreatic cancer was analyzed and compared with that of conventional CT.
    Results A total of 134 patients were included in the study: 127 with pancreatic cancers and 7 with benign lesions. Detection rates of 68Ga-FAPI-04 PET/CT for primary pancreatic cancers, regional lymph node metastasis, and distant metastasis were 100% (127/127), 68.63% (35/51), and 95.35% (41/43), respectively. Median standard uptake value maxium (SUVmax) of pancreatic cancers (14.9) was significantly higher than that of benign pancreatic lesions (6.1) (Z value = -2.921, P= 0.003). TNM staging changed in 32.28% (41/127) pancreatic cancer patients after 68Ga-FAPI PET/CT than in 3.94% (5/127) who underwent conventional CT; consequently, some patients changed their treatment plan.
    Conclusions 68Ga-FAPI-04 PET/CT has high diagnostic sensitivity for pancreatic cancer and can detect more cases of distant metastatic lesions and improve M staging compared to that by conventional CT, thereby facilitating a more comprehensive assessment of systemic tumor burden and treatment planning.

     

    • HTML全文
    • 参考文献(17)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回